This HTML5 document contains 93 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n22http://linked.opendata.cz/resource/mesh/concept/
n4http://linked.opendata.cz/resource/drugbank/company/
n15http://linked.opendata.cz/resource/drugbank/dosage/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00220/identifier/wikipedia/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00220/identifier/pharmgkb/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00220/identifier/kegg-compound/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00220/identifier/bindingdb/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00220/identifier/pubchem-compound/
n24http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n6http://linked.opendata.cz/resource/drugbank/drug/DB00220/identifier/pubchem-substance/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00220/identifier/drugbank/
n9http://linked.opendata.cz/resource/drugbank/patent/
n31http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n19http://linked.opendata.cz/resource/drugbank/medicinal-product/
n21http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n12http://www.drugs.com/cdi/
n16http://www.rxlist.com/cgi/generic2/
n28http://linked.opendata.cz/resource/drugbank/drug/DB00220/identifier/national-drug-code-directory/
n13http://linked.opendata.cz/resource/drugbank/property/
n8http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n18http://linked.opendata.cz/resource/atc/
n25http://linked.opendata.cz/resource/drugbank/drug/DB00220/identifier/chemspider/
n17http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00220
rdf:type
n3:Drug
n3:description
A potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. [PubChem]
n3:dosage
n15:271B5F12-363D-11E5-9242-09173F13E4C5 n15:271B5F13-363D-11E5-9242-09173F13E4C5 n15:271B5F14-363D-11E5-9242-09173F13E4C5 n15:271B5F15-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Kaldor SW, Kalish VJ, Davies JF 2nd, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH: Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997 Nov 21;40(24):3979-85. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9397180
n3:group
approved
n3:halfLife
3.5 - 5 hours
n3:indication
Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.
n3:manufacturer
n4:271B5F0E-363D-11E5-9242-09173F13E4C5
owl:sameAs
n24:DB00220 n31:DB00220
dcterms:title
Nelfinavir
adms:identifier
n6:46507719 n10:PA450606 n11:Nelfinavir n25:57718 n26:DB00220 n27:518 n28:63010-010-30 n29:64143 n30:C07257
n3:mechanismOfAction
Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.
n3:packager
n4:271B5F0D-363D-11E5-9242-09173F13E4C5 n4:271B5F0B-363D-11E5-9242-09173F13E4C5 n4:271B5F0C-363D-11E5-9242-09173F13E4C5 n4:271B5F09-363D-11E5-9242-09173F13E4C5 n4:271B5F0A-363D-11E5-9242-09173F13E4C5 n4:271B5F07-363D-11E5-9242-09173F13E4C5 n4:271B5F08-363D-11E5-9242-09173F13E4C5 n4:271B5F05-363D-11E5-9242-09173F13E4C5 n4:271B5F06-363D-11E5-9242-09173F13E4C5 n4:271B5F03-363D-11E5-9242-09173F13E4C5 n4:271B5F04-363D-11E5-9242-09173F13E4C5 n4:271B5F01-363D-11E5-9242-09173F13E4C5 n4:271B5F02-363D-11E5-9242-09173F13E4C5 n4:271B5EFF-363D-11E5-9242-09173F13E4C5 n4:271B5F00-363D-11E5-9242-09173F13E4C5 n4:271B5EFD-363D-11E5-9242-09173F13E4C5 n4:271B5EFE-363D-11E5-9242-09173F13E4C5
n3:patent
n9:5484926 n9:2173328
n3:routeOfElimination
The terminal half-life in plasma was typically 3.5 to 5 hours. The majority (87%) of an oral 750 mg dose containing 14C-nelfinavir was recovered in the feces; fecal radioactivity consisted of numerous oxidative metabolites (78%) and unchanged nelfinavir (22%). Only 1–2% of the dose was recovered in urine, of which unchanged nelfinavir was the major component.
n3:synonym
Viracept
n3:toxicity
Oral LD<sub>50</sub> is over 5g/kg in rats. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.
n3:volumeOfDistribution
* 2 to 7 L/kg
n17:hasAHFSCode
n20:08-18-08-08
n3:foodInteraction
Take with food. Food significantly increases absorption (2 to 3 times).
n3:proteinBinding
&gt;98%
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Nelfinavir.htm
n21:hasConcept
n22:M0029531
foaf:page
n8:vir1483.shtml n12:nelfinavir.html n16:nelfin.htm
n3:IUPAC-Name
n13:271B5F1A-363D-11E5-9242-09173F13E4C5
n3:InChI
n13:271B5F20-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n13:271B5F1F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n13:271B5F1C-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n13:271B5F1D-363D-11E5-9242-09173F13E4C5
n3:SMILES
n13:271B5F1E-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n13:271B5F18-363D-11E5-9242-09173F13E4C5 n13:271B5F30-363D-11E5-9242-09173F13E4C5
n3:logP
n13:271B5F19-363D-11E5-9242-09173F13E4C5 n13:271B5F16-363D-11E5-9242-09173F13E4C5 n13:271B5F32-363D-11E5-9242-09173F13E4C5
n3:logS
n13:271B5F17-363D-11E5-9242-09173F13E4C5
n17:hasATCCode
n18:J05AE04
n3:H-Bond-Acceptor-Count
n13:271B5F26-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n13:271B5F27-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n13:271B5F21-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n13:271B5F22-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n13:271B5F24-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n13:271B5F23-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n13:271B5F25-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed following oral administration.
n3:affectedOrganism
Human Immunodeficiency Virus
n3:casRegistryNumber
159989-64-7
n3:containedIn
n19:271B5F11-363D-11E5-9242-09173F13E4C5 n19:271B5F0F-363D-11E5-9242-09173F13E4C5 n19:271B5F10-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n13:271B5F2C-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n13:271B5F2E-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n13:271B5F2F-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n13:271B5F31-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n13:271B5F2B-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n13:271B5F2A-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n13:271B5F2D-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n13:271B5F1B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n13:271B5F28-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n13:271B5F29-363D-11E5-9242-09173F13E4C5